Balaji Amines Declares ₹11 Dividend; FY26 Consolidated PAT ₹169 Crore

CHEMICALS
Whalesbook Corporate News Logo
AuthorVihaan Mehta|Published at:
Balaji Amines Declares ₹11 Dividend; FY26 Consolidated PAT ₹169 Crore

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Balaji Amines announced a ₹11 per share dividend and reported consolidated PAT of ₹169.16 crore for FY26. The company expects strong volume growth driven by new specialty chemical projects.

Balaji Amines Eyes Growth with ₹11 Dividend and New Projects

Balaji Amines reported a consolidated Profit After Tax (PAT) of ₹169.16 crore for the financial year 2025-26. The company also announced an interim dividend of ₹11 per share.

Reader Takeaway: Strong FY26 PAT and new EV battery projects signal growth, but feedstock costs remain a concern.

What just happened

Balaji Amines announced a consolidated Profit After Tax (PAT) of ₹169.16 crore for the financial year 2025-26. This marks an increase from ₹158.59 crore in the previous fiscal year. The company also declared an interim dividend of ₹11 per share. Consolidated revenue from operations stood at ₹1,424.98 crore for FY26, up from ₹1,397.08 crore in FY25.

Why this matters

The results indicate a turnaround for the company after two years of subdued global specialty chemical pricing. Management guidance for FY27 anticipates 10–15% consolidated volume growth and EBITDA margins of 22–23%. Medium-term projections point to 20–30% volume growth fueled by new projects like Dimethyl Ether (DME), N-Methyl-2-pyrrolidone (NMP), Acrylonitrile (ACN), and the expansion at its subsidiary, Balaji Speciality Chemicals Limited (BSCL).

The backstory

Balaji Amines has focused on developing indigenous technology to reduce reliance on external licenses. Key operational milestones in FY26 included the commissioning of India's first electronic-grade Dimethyl Carbonate (DMC) plant in May 2025, aiming to supply the EV battery sector.

What changes now

The company is entering a new growth phase with significant capital expenditure. The ₹750 crore capex expansion at BSCL has received 'Mega Project' status from the Maharashtra government. Unit I of the BSCL expansion is expected by September 2026, with Unit II by the end of FY27. The Dimethyl Ether (DME) plant was commissioned in Q1 FY27.

Risks to watch

Investors should note the company's dependence on imported feedstocks like ammonia and methanol. Additionally, the competitive landscape is influenced by low-cost Chinese imports. Geopolitical risks, such as Middle East tensions, could impact logistics and profitability.

Peer comparison

While specific peer data for this period was not provided in the filing, the specialty chemical sector in India is competitive, with several players vying for market share in high-growth segments like EV batteries and import substitution.

Context metrics (time-bound)

  • FY26 Consolidated PAT: ₹169.16 crore
  • FY25 Consolidated PAT: ₹158.59 crore
  • FY26 Consolidated Revenue: ₹1,424.98 crore
  • FY25 Consolidated Revenue: ₹1,397.08 crore
  • Dividend Announced: ₹11 per share
  • BSCL Capex: ₹750 crore

What to track next

Investors should closely monitor the commissioning timelines for the BSCL subsidiary's expansion projects and the ramp-up in demand for its new products, particularly in the EV battery and specialty chemical segments.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This article is published for informational purposes only. While reasonable efforts are made to ensure accuracy, completeness, and timeliness, readers are encouraged to independently verify information before making any decisions based on the content. The views and information presented are subject to editorial review and may be updated without notice.